Quick Comparison

L-TheaninePEA (Palmitoylethanolamide)
Half-Life2.5-4.5 hours1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability
Typical DosageStandard: 100-200 mg daily. With caffeine: 100-200 mg L-Theanine per 50-100 mg caffeine (2:1 or 1:1 ratio). Can be taken up to 400 mg daily safely.Standard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks.
AdministrationOral (capsules, powder, naturally in green tea). 100% bioavailable orally.Oral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability.
Research Papers10 papers10 papers
Categories

Mechanism of Action

L-Theanine

L-Theanine (gamma-glutamylethylamide) crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1/SLC7A5) and exerts anxiolytic effects through multiple pathways. It increases GABA synthesis by serving as a substrate for glutamate decarboxylase (GAD), elevating inhibitory tone without directly binding GABA-A receptors — avoiding sedation. It modulates serotonin by increasing tryptophan hydroxylase (TPH2) activity and raises dopamine levels in the prefrontal cortex via inhibition of dopamine reuptake. L-Theanine antagonizes glutamate binding at AMPA and kainate receptor subtypes (GluA1-4, GluK1-5), reducing excitatory neurotransmission and excitotoxicity risk. This glutamate antagonism, combined with increased GABA, drives the characteristic increase in alpha brain wave power (8-14 Hz) in the posterior parietal and occipital cortex — the EEG signature of relaxed alertness. When co-administered with caffeine, L-theanine attenuates caffeine-induced increases in blood pressure and anxiety by modulating sympathetic nervous system activation through alpha-2 adrenergic receptor pathways, while caffeine's dopaminergic and adenosine-blocking effects on focus and attention are preserved.

PEA (Palmitoylethanolamide)

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.

Risks & Safety

L-Theanine

Common

Very few side effects at standard doses. Mild drowsiness in some individuals.

Serious

None documented. Extremely safe with decades of human consumption data.

Rare

Headache, dizziness, gastrointestinal discomfort.

PEA (Palmitoylethanolamide)

Common

Very well-tolerated — rare side effects. Mild GI discomfort.

Serious

None documented. Over 30 clinical trials confirm excellent safety profile.

Rare

Skin rash.

Full Profiles